US2009203615A1PendingUtilityA1
Use of activity dependent neurotrophic factor for enhancing learning and memory: pre-and post-natal administration
Assignee: US GOV HEALTH & HUMAN SERVPriority: May 31, 2000Filed: Aug 25, 2008Published: Aug 13, 2009
Est. expiryMay 31, 2020(expired)· nominal 20-yr term from priority
A61P 43/00A61P 9/00A61P 31/18A61P 9/10A61P 3/10A61P 35/00A61P 25/00A61P 25/14A61P 25/16A61P 25/28A61P 25/32A61P 25/18A61P 25/08A61P 21/04A61K 38/00A61P 17/02C07K 14/475
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides methods for improving performance (e.g., learning and/or memory) using ADNF polypeptides, by treating the subject prenatally or postnatally with an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject.
Claims
exact text as granted — not AI-modified1 . A method for improving learning and/or memory in a subject, the method comprising the step of administering postnatally to the subject an Activity Dependent Neurotrophic Factor (ADNF) polypeptide in an amount sufficient to improve postnatal learning and/or memory of the subject, wherein the ADNF polypeptide is a member selected from the group consisting of:
(a) an ADNF I polypeptide comprising an active core site having the following amino acid sequence:
Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala;
(SEQ ID NO: 1)
(b) an ADNF III polypeptide comprising an active core site having the following amino acid sequence:
Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln.
(SEQ ID NO:2)
.
2 . (canceled)
3 . The method of claim 1 , wherein the ADNF polypeptide is an ADNF I polypeptide.
4 . The method of claim 3 , wherein the active core site of the ADNF I polypeptide comprises at least one D-amino acid.
5 . The method of claim 3 , wherein the active core site of the ADNF I polypeptide comprises all D-amino acids.
6 . The method of claim 3 , wherein the ADNF I polypeptide is Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala (SEQ ID NO:1).
7 . The method of claim 3 , wherein the ADNF I polypeptide is selected from the group consisting of:
(SEQ ID NO: 14)
Val-Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-
Ile-Pro-Ala;
(SEQ ID NO: 15)
Val-Glu-Glu-Gly-Ile-Val-Leu-Gly-Gly-Gly-Ser-Ala-
Leu-Leu-Arg-Ser-Ile-Pro-Ala;
(SEQ ID NO: 16)
Leu-Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-
Ala;
(SEQ ID NO: 17)
Gly-Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala;
(SEQ ID NO: 18)
Gly-Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala;
(SEQ ID NO: 19)
Gly-Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala;
and
(SEQ ID NO: 1)
Ser-Ala-Leu-Leu-Arg-Ser-Ile-Pro-Ala.
8 . The method of claim 3 , wherein the ADNF I polypeptide comprises up to about 20 amino acids at least one of the N-terminus and the C-terminus of the active core site.
9 . The method of claim 1 , wherein the ADNF polypeptide is an ADNF III polypeptide.
10 . The method of claim 9 , wherein the ADNF III polypeptide is Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln (SEQ ID NO:2).
11 . The method of claim 9 , wherein the active core site of the ADNF III polypeptide comprises at least one D-amino acid.
12 . The method of claim 9 , wherein the active core site of the ADNF III polypeptide comprises all D-amino acids.
13 . The method of claim 9 , wherein the ADNF III polypeptide is a member selected from the group consisting of:
(SEQ ID NO: 20)
Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln;
(SEQ ID NO: 21)
Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln-
Gln-Ser;
(SEQ ID NO: 22)
Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-Ser-Ile-Pro-
Gln-Gln-Ser;
(SEQ ID NO: 23)
Ser-Val-Arg-Leu-Gly-Leu-Gly-Gly-Asn-Ala-Pro-Val-
Ser-Ile-Pro-Gln-Gln-Ser;
and
(SEQ ID NO: 2)
Asn-Ala-Pro-Val-Ser-Ile-Pro-Gln.
14 . The method of claim 9 , wherein the ADNF III polypeptide comprises up to about 20 amino acids at least one of the N-terminus and the C-terminus of the active core site.
15 - 21 . (canceled)
22 . The method of claim 1 , wherein the subject is afflicted with a neuropathology.
23 . The method of claim 1 , wherein the subject has Alzheimer's disease.
24 . The method of claim 1 , wherein the subject has Down's syndrome.
25 . The method of claim 1 , wherein the subject is normal.
26 . The method of claim 25 , wherein the subject is old.
27 . The method of claim 1 , wherein the method improves short term memory.
28 . The method of claim 1 , wherein the method improves reference memory.
29 . The method of claim 1 , wherein the ADNF polypeptide is administered intranasally or orally.
30 - 59 . (canceled)Join the waitlist — get patent alerts
Track US2009203615A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.